73. Kensil CR, Wu Jy, Soltisyk S. Structural and immunological characterization of the vaccine adjuvant QS-21. In Vaccine
design: the subunit and adjuvant approach. Powell NM, editor. New York: Plenum Press; 1995;p. 525–541
74. Rook GA. New meanings for an old word: adjuvanticity, cytokines and T cells. Immunol Today 1993;14:95–96.
75. Mbawuike I, Zang Y, Couch RB. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with
or without QS21 adjuvant. Vaccine 2007;25:3263–3269.
76. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D. Phase 1 trial of immunological adjuvant
QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994;12:1275–1280.
77. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, et al. Induction of antibodies against GM2 ganglioside by
immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res;2000
6:874–879.
78. Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, et al. Safety, tolerability and immunogenicity of new formulations
of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002;20:2263–2277.
79. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG. Prototype Alzheimer's disease
epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 2006;24:2275–2282.
80. Rimmelzwaan GF, Baars M, van Beek R, van Amerongen G, Lovgren-Bengtsson K, Claas EC, Osterhaus AD. Induction of protective
immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 1997;78 (
Pt 4):757–765.
81. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization
with purified HIV-1 envelope protein in ISCOMs. Nature 1990;344:873–875.
82. Cox JC, Sjolander A, Barr IG. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998;32:247–271.
83. Soltysik S, Wu JY, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR. Structure/function studies of QS-21 adjuvant:
assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine;1995 13:1403–1410.
84. Morein B, Villacres-Eriksson M, Lovgren-Bengtsson K. Iscom, a delivery system for parenteral and mucosal vaccination.
Dev Biol Stand 1998;92:33–39.
85. Claassen I, Osterhaus A. The iscom structure as an immune-enhancing moiety: experience with viral systems. Res Immunol
1992;143:531–541.
86. Davis ID, Chen W, Jackson, H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX
adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101:10697–10702.
87. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252:252.
88. Heath TD, Edwards DC, Ryman BE. The adjuvant properties of liposomes. Biochem Soc Trans 1976;4:129–133.
89. Tyrrell DA, Heath TD, Colley CM, Ryman BE. New aspects of liposomes. Biochim Biophys Acta 1976;457:259–302.
90. van Rooijen N, van Nieuwmegen R. Use of liposomes as biodegradable and harmless adjuvants. Methods Enzymol 1983;93:83–95.
91. Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM. Biodegradable microspheres as a vaccine delivery system.
Mol Immunol 1991;28:287–294.
|
